NASDAQ:KRYS - Krystal Biotech Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$10.18 -0.07 (-0.68 %)
(As of 05/25/2018 04:43 AM ET)
Previous Close$10.25
Today's Range$10.11 - $10.97
52-Week Range$8.03 - $12.00
Volume28,400 shs
Average Volume16,210 shs
Market Capitalization$108.25 million
P/E Ratio-6.88
Dividend YieldN/A
BetaN/A

About Krystal Biotech (NASDAQ:KRYS)

Krystal Biotech, Inc., a gene therapy company, develops and commercializes pharmaceutical products for patients suffering from dermatological diseases in the United States. The company's lead product candidate is KB103, which is in preclinical development to treat dystrophic epidermolysis bullosa, a genetic disease. It also engages in developing KB105, which is in preclinical studies to treat Lamellar Ichthyosis, which is an autosomal recessive disorder. The company was formerly known as Krystal Biotech, LLC and changed its name to Krystal Biotech, Inc. in March 2017. Krystal Biotech, Inc. was founded in 2015 and is based in Pittsburgh, Pennsylvania.

Receive KRYS News and Ratings via Email

Sign-up to receive the latest news and ratings for KRYS and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:KRYS
CUSIPN/A
Phone412-586-5830

Debt

Debt-to-Equity RatioN/A
Current Ratio105.91
Quick Ratio105.91

Price-To-Earnings

Trailing P/E Ratio-6.88
Forward P/E Ratio-4.61
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$4.60 per share
Price / Book2.21

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A

Miscellaneous

Employees12
Outstanding Shares10,310,000

Krystal Biotech (NASDAQ:KRYS) Frequently Asked Questions

What is Krystal Biotech's stock symbol?

Krystal Biotech trades on the NASDAQ under the ticker symbol "KRYS."

How were Krystal Biotech's earnings last quarter?

Krystal Biotech (NASDAQ:KRYS) released its earnings results on Monday, May, 7th. The company reported ($0.21) earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of ($0.48) by $0.27. View Krystal Biotech's Earnings History.

What price target have analysts set for KRYS?

1 equities research analysts have issued 1 year price objectives for Krystal Biotech's stock. Their predictions range from $23.00 to $23.00. On average, they expect Krystal Biotech's stock price to reach $23.00 in the next year. View Analyst Ratings for Krystal Biotech.

Who are some of Krystal Biotech's key competitors?

Who are Krystal Biotech's key executives?

Krystal Biotech's management team includes the folowing people:
  • Mr. Krish S. Krishnan M.S., M.B.A., Pres, CEO & Chairman (Age 53)
  • Ms. Suma M. Krishnan, Founder, COO & Director (Age 53)
  • Ms. Pooja Agarwal, VP of Product Devel.
  • Mr. Michael C. Sheahan CPA, Interim Chief Financial Officer

When did Krystal Biotech IPO?

(KRYS) raised $30 million in an initial public offering (IPO) on Wednesday, September 20th 2017. The company issued 3,000,000 shares at a price of $9.00-$11.00 per share. Ladenburg Thalmann acted as the underwriter for the IPO.

Has Krystal Biotech been receiving favorable news coverage?

News headlines about KRYS stock have been trending somewhat positive this week, Accern Sentiment reports. The research group identifies positive and negative press coverage by monitoring more than 20 million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Krystal Biotech earned a daily sentiment score of 0.09 on Accern's scale. They also gave news coverage about the company an impact score of 46.62 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock's share price in the immediate future.

Who are Krystal Biotech's major shareholders?

Krystal Biotech's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Millennium Management LLC (0.17%). Company insiders that own Krystal Biotech stock include Antony A Riley, Daniel Janney, Krish S Krishnan, R Douglas Norby and Suma Krishnan. View Institutional Ownership Trends for Krystal Biotech.

Which institutional investors are selling Krystal Biotech stock?

KRYS stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC. View Insider Buying and Selling for Krystal Biotech.

How do I buy shares of Krystal Biotech?

Shares of KRYS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Krystal Biotech's stock price today?

One share of KRYS stock can currently be purchased for approximately $10.18.

How big of a company is Krystal Biotech?

Krystal Biotech has a market capitalization of $108.25 million. The company earns $-7,920,000.00 in net income (profit) each year or ($1.48) on an earnings per share basis. Krystal Biotech employs 12 workers across the globe.

How can I contact Krystal Biotech?

Krystal Biotech's mailing address is 2100 WHARTON STREET SUITE 701, PITTSBURGH PA, 15203. The company can be reached via phone at 412-586-5830.


MarketBeat Community Rating for Krystal Biotech (KRYS)

Community Ranking:  2.0 out of 5 (star star)
Outperform Votes:  58 (Vote Outperform)
Underperform Votes:  85 (Vote Underperform)
Total Votes:  143
MarketBeat's community ratings are surveys of what our community members think about Krystal Biotech and other stocks. Vote "Outperform" if you believe KRYS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe KRYS will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Krystal Biotech (NASDAQ:KRYS) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
1 Wall Street analysts have issued ratings and price targets for Krystal Biotech in the last 12 months. Their average twelve-month price target is $23.00, suggesting that the stock has a possible upside of 125.93%. The high price target for KRYS is $23.00 and the low price target for KRYS is $23.00. There are currently 1 buy rating for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $23.00$23.00$23.00$23.00
Price Target Upside: 125.93% upside136.87% upside136.87% upside136.87% upside

Krystal Biotech (NASDAQ:KRYS) Consensus Price Target History

Price Target History for Krystal Biotech (NASDAQ:KRYS)

Krystal Biotech (NASDAQ:KRYS) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
10/18/2017Ladenburg ThalmannInitiated CoverageBuy ➝ Buy$23.00N/AView Rating Details
(Data available from 5/25/2016 forward)

Earnings

Krystal Biotech (NASDAQ:KRYS) Earnings History and Estimates Chart

Earnings by Quarter for Krystal Biotech (NASDAQ:KRYS)

Krystal Biotech (NASDAQ:KRYS) Earnings Estimates

Current Year EPS Consensus Estimate: $-2.21 EPS
Next Year EPS Consensus Estimate: $-2.41 EPS

Krystal Biotech (NASDAQ KRYS) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/7/20183/31/2018($0.48)($0.21)ViewN/AView Earnings Details
11/13/2017Q3 2017($0.74)($1.26)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Krystal Biotech (NASDAQ:KRYS) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Krystal Biotech (NASDAQ KRYS) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 45.80%
Institutional Ownership Percentage: 29.82%
Insider Trading History for Krystal Biotech (NASDAQ:KRYS)

Krystal Biotech (NASDAQ KRYS) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
5/22/2018Antony A RileyCFOBuy2,800$10.75$30,100.00View SEC Filing  
5/9/2018R Douglas NorbyDirectorBuy9,000$10.42$93,780.00View SEC Filing  
3/19/2018Krish S KrishnanInsiderBuy50,000$11.00$550,000.00View SEC Filing  
9/22/2017Daniel JanneyDirectorBuy200,000$10.00$2,000,000.00View SEC Filing  
9/22/2017Suma KrishnanCOOBuy100,000$10.00$1,000,000.001,935,249View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Krystal Biotech (NASDAQ KRYS) News Headlines

Source:
DateHeadline
Krystal Biotech (KRYS) CFO Antony A. Riley Purchases 2,800 SharesKrystal Biotech (KRYS) CFO Antony A. Riley Purchases 2,800 Shares
www.americanbankingnews.com - May 24 at 8:17 PM
Krystal Biotechs KB103 Fast Trackd for rare skin blistering disorder; shares up 3%Krystal Biotech's KB103 Fast Track'd for rare skin blistering disorder; shares up 3%
seekingalpha.com - May 24 at 4:22 PM
BRIEF-U.S. FDA Grants Fast Track Designation For Krystal Biotech’S Kb103BRIEF-U.S. FDA Grants Fast Track Designation For Krystal Biotech’S Kb103
www.reuters.com - May 24 at 9:46 AM
U.S. FDA Grants Fast Track Designation for Krystal Biotech’s KB103 for the Treatment of Dystrophic Epidermolysis BullosaU.S. FDA Grants Fast Track Designation for Krystal Biotech’s KB103 for the Treatment of Dystrophic Epidermolysis Bullosa
finance.yahoo.com - May 24 at 9:46 AM
Krystal Biotech (KRYS) Lifted to Hold at Zacks Investment ResearchKrystal Biotech (KRYS) Lifted to Hold at Zacks Investment Research
www.americanbankingnews.com - May 16 at 3:41 PM
Krystal Biotech (KRYS) Director Buys $93,780.00 in StockKrystal Biotech (KRYS) Director Buys $93,780.00 in Stock
www.americanbankingnews.com - May 11 at 8:21 PM
Krystal Biotech Announces Dosing of First Patient in the Phase 1/2 trial of KB103, a First-in-ClassKrystal Biotech Announces Dosing of First Patient in the Phase 1/2 trial of KB103, a First-in-Class
www.nasdaq.com - May 10 at 9:51 AM
Krystal Biotech Announces Dosing of First Patient in the Phase 1/2 trial of KB103, a First-in-Class Topical Gene Therapy for the Treatment of Dystrophic Epidermolysis BullosaKrystal Biotech Announces Dosing of First Patient in the Phase 1/2 trial of KB103, a First-in-Class Topical Gene Therapy for the Treatment of Dystrophic Epidermolysis Bullosa
finance.yahoo.com - May 10 at 9:51 AM
Krystal Biotech Presents In Vivo KB103 Data at the International Investigative Dermatology Conference that Show Human COL7 Incorporating into Anchoring Fibrils with Proper Structural OrientationKrystal Biotech Presents In Vivo KB103 Data at the International Investigative Dermatology Conference that Show Human COL7 Incorporating into Anchoring Fibrils with Proper Structural Orientation
finance.yahoo.com - May 9 at 9:40 AM
Krystal Biotech (KRYS) Issues  Earnings ResultsKrystal Biotech (KRYS) Issues Earnings Results
www.americanbankingnews.com - May 8 at 12:44 PM
Krystal Biotech Reports First Quarter 2018 Financial Results and Provides Corporate UpdateKrystal Biotech Reports First Quarter 2018 Financial Results and Provides Corporate Update
finance.yahoo.com - May 7 at 9:28 AM
ValuEngine Upgrades Krystal Biotech (KRYS) to "Hold"ValuEngine Upgrades Krystal Biotech (KRYS) to "Hold"
www.americanbankingnews.com - May 3 at 11:51 PM
FDA on board with clinical development of Krystal Biotechs KB103 for skin blistering disorder; shares up 3%FDA on board with clinical development of Krystal Biotech's KB103 for skin blistering disorder; shares up 3%
seekingalpha.com - April 26 at 10:16 AM
BRIEF-Krystal Biotech Announces FDA Clearance Of IND On KB103 For The Treatment Of Dystrophic Epidermolysis BullosaBRIEF-Krystal Biotech Announces FDA Clearance Of IND On KB103 For The Treatment Of Dystrophic Epidermolysis Bullosa
www.reuters.com - April 26 at 9:26 AM
Krystal Biotech Announces FDA Clearance of IND on KB103 to Begin Enrolling Patients for the Treatment of Dystrophic Epidermolysis BullosaKrystal Biotech Announces FDA Clearance of IND on KB103 to Begin Enrolling Patients for the Treatment of Dystrophic Epidermolysis Bullosa
finance.yahoo.com - April 26 at 9:26 AM
Krystal Biotechs KB103 an Orphan Drug in Europe for DEBKrystal Biotech's KB103 an Orphan Drug in Europe for DEB
seekingalpha.com - April 19 at 4:30 PM
Krystal Biotech receives approval in Europe for gene therapy treatmentKrystal Biotech receives approval in Europe for gene therapy treatment
www.bizjournals.com - April 19 at 4:30 PM
Krystal Biotech’s KB103 Receives Orphan Medicinal Product Designation in Europe for Dystrophic Epidermolysis BullosaKrystal Biotech’s KB103 Receives Orphan Medicinal Product Designation in Europe for Dystrophic Epidermolysis Bullosa
finance.yahoo.com - April 19 at 9:41 AM
Catalyst Pipeline Portfolio Updates - Strong Start To For The PortfolioCatalyst Pipeline Portfolio Updates - Strong Start To For The Portfolio
seekingalpha.com - April 18 at 4:33 PM
Krystal Biotech Presents Their Skin TARgeted Delivery Platform at the World Orphan Drug Congress USAKrystal Biotech Presents Their Skin TARgeted Delivery Platform at the World Orphan Drug Congress USA
finance.yahoo.com - April 18 at 4:33 PM
Reader Inquiry: Why Is Krystal Biotech Not Participating In The Rally In Gene Therapy Stocks?Reader Inquiry: Why Is Krystal Biotech Not Participating In The Rally In Gene Therapy Stocks?
seekingalpha.com - April 17 at 9:58 AM
Ladenburg Thalmann Financial Services Begins Coverage on Krystal Biotech (KRYS)Ladenburg Thalmann Financial Services Begins Coverage on Krystal Biotech (KRYS)
www.americanbankingnews.com - April 6 at 3:32 PM
Zacks Investment Research Upgrades Krystal Biotech (KRYS) to HoldZacks Investment Research Upgrades Krystal Biotech (KRYS) to Hold
www.americanbankingnews.com - March 30 at 11:10 PM
Krystal Biotech submits IND for gene therapy KB103 for rare skin blistering disorderKrystal Biotech submits IND for gene therapy KB103 for rare skin blistering disorder
seekingalpha.com - March 27 at 10:07 AM
Krystal Submits Investigational New Drug (IND) Application for KB103, Topical Gene Therapy Candidate for Dystrophic Epidermolysis BullosaKrystal Submits Investigational New Drug (IND) Application for KB103, Topical Gene Therapy Candidate for Dystrophic Epidermolysis Bullosa
finance.yahoo.com - March 27 at 10:07 AM
Krystal Biotech Inc (KRYS) Insider Buys $550,000.00 in StockKrystal Biotech Inc (KRYS) Insider Buys $550,000.00 in Stock
www.americanbankingnews.com - March 19 at 7:28 PM
Krystal Biotech (KRYS) Downgraded by Zacks Investment ResearchKrystal Biotech (KRYS) Downgraded by Zacks Investment Research
www.americanbankingnews.com - March 17 at 2:08 PM
Krystal Biotech Reports 2017 Financial Results and Business ProgressKrystal Biotech Reports 2017 Financial Results and Business Progress
finance.yahoo.com - March 12 at 10:36 AM
Krystal Biotech Incs Lock-Up Period Will End  on March 19th (NASDAQ:KRYS)Krystal Biotech Inc's Lock-Up Period Will End on March 19th (NASDAQ:KRYS)
www.americanbankingnews.com - March 12 at 1:24 AM
Krystal Biotech, Inc. to Present at the 30th Annual ROTH ConferenceKrystal Biotech, Inc. to Present at the 30th Annual ROTH Conference
finance.yahoo.com - March 5 at 9:57 AM
Krystal Biotech, Inc. Announces Granting of U.S. Composition of Matter Patent Covering Herpes Simplex Virus (HSV) Vectors and Methods of Using the Same to Treat Skin DiseasesKrystal Biotech, Inc. Announces Granting of U.S. Composition of Matter Patent Covering Herpes Simplex Virus (HSV) Vectors and Methods of Using the Same to Treat Skin Diseases
finance.yahoo.com - January 16 at 8:56 AM
Zacks Investment Research Downgrades Krystal Biotech (KRYS) to SellZacks Investment Research Downgrades Krystal Biotech (KRYS) to Sell
www.americanbankingnews.com - December 24 at 11:12 AM
Krystal Biotech, Inc. (KRYS) Announces Quarterly  Earnings Results, Misses Estimates By $0.52 EPSKrystal Biotech, Inc. (KRYS) Announces Quarterly Earnings Results, Misses Estimates By $0.52 EPS
www.americanbankingnews.com - November 14 at 10:32 AM
BRIEF-Krystal Biotech reports qtrly loss per share $1.26‍BRIEF-Krystal Biotech reports qtrly loss per share $1.26‍
www.reuters.com - November 14 at 1:56 AM
Krystal Biotech Reports that KB103 Received Clearance From RAC Review and Announces Third Quarter 2017 Financial ResultsKrystal Biotech Reports that KB103 Received Clearance From RAC Review and Announces Third Quarter 2017 Financial Results
finance.yahoo.com - November 13 at 8:55 PM
Krystal Biotech (KRYS) Announces KB103 Granted Orphan Drug Designation by FDA to Treat Patients With DEBKrystal Biotech (KRYS) Announces KB103 Granted Orphan Drug Designation by FDA to Treat Patients With DEB
www.streetinsider.com - November 9 at 7:46 AM
Krystal Biotech’s KB103 Granted Orphan Drug Designation by the FDA to Treat Patients With Dystrophic Epidermolysis BullosaKrystal Biotech’s KB103 Granted Orphan Drug Designation by the FDA to Treat Patients With Dystrophic Epidermolysis Bullosa
finance.yahoo.com - November 8 at 12:47 PM
Krystal Biotech Receives Equity-Based Award from EB Research Partnership and EB Medical Research FoundationKrystal Biotech Receives Equity-Based Award from EB Research Partnership and EB Medical Research Foundation
finance.yahoo.com - November 3 at 1:13 PM
Krystal Biotech Incs Quiet Period To Expire  on October 30th (NASDAQ:KRYS)Krystal Biotech Inc's Quiet Period To Expire on October 30th (NASDAQ:KRYS)
www.americanbankingnews.com - October 23 at 1:22 AM
Is Krystal Biotech Inc (KRYS) Still A Cheap Healthcare Stock?Is Krystal Biotech Inc (KRYS) Still A Cheap Healthcare Stock?
finance.yahoo.com - October 21 at 5:31 AM
Krystal Biotech Inc (KRYS) President and CEO Krish S Krishnan Bought $1,000,000 of SharesKrystal Biotech Inc (KRYS) President and CEO Krish S Krishnan Bought $1,000,000 of Shares
finance.yahoo.com - September 26 at 8:07 AM
Krystal Biotech Inc (KRYS) COO Suma Krishnan Purchases 100,000 SharesKrystal Biotech Inc (KRYS) COO Suma Krishnan Purchases 100,000 Shares
www.americanbankingnews.com - September 25 at 7:14 PM
Krystal Biotech Inc (KRYS) Director Daniel Janney Acquires 200,000 SharesKrystal Biotech Inc (KRYS) Director Daniel Janney Acquires 200,000 Shares
www.americanbankingnews.com - September 25 at 7:14 PM
Krystal Biotech Prices IPO at $9.00-$11.00 Per Share (KRYS)Krystal Biotech Prices IPO at $9.00-$11.00 Per Share (KRYS)
www.americanbankingnews.com - September 8 at 1:24 AM

SEC Filings

Krystal Biotech (NASDAQ:KRYS) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Krystal Biotech (NASDAQ:KRYS) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Krystal Biotech (NASDAQ KRYS) Stock Chart for Friday, May, 25, 2018

Loading chart…

This page was last updated on 5/25/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.